Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST‐CLI) Trial

Open access
Menard, Matthew T., Farber, Alik, Assmann, Susan F., Choudhry, Niteesh K., Conte, Michael S., Creager, Mark A., Dake, Michael D., Jaff, Michael R., Kaufman, John A., Powell, Richard J., Reid, Diane M., Siami, Flora Sandra, Sopko, George, White, Christopher J., Rosenfield, Kenneth·2016·Journal of the American Heart Association

Abstract

Background: Critical limb ischemia ( CLI ) is increasing in prevalence, and remains a significant source of mortality and limb loss. The decision to recommend surgical or endovascular revascularization for patients who are candidates for both varies significantly among providers and is driven more by individual preference than scientific evidence. Methods and Results: The Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST‐CLI) Trial is a prospective, randomized, multidisciplinary, controlled, superiority trial designed to compare treatment efficacy, functional outcomes, quality of life, and cost in patients undergoing best endovascular or best open surgical revascularization. Approximately 140 clinical sites in the United States and Canada will enroll 2100 patients with CLI who are candidates for both treatment options. A pragmatic trial design requires consensus on patient eligibility by at least 2 investigators, but leaves the choice of specific procedural strategy within the assigned revascularization approach to the individual treating investigator. Patients with suitable single‐segment of saphenous vein available for potential bypass will be randomized within Cohort 1 (n=1620), while patients without will be randomized within Cohort 2 (n=480). The primary efficacy end point of the trial is Major Adverse Limb Event–Free Survival. Key secondary end points include Re‐intervention and Amputation‐Free‐Survival and Amputation Free‐Survival. Conclusions: The BEST ‐ CLI trial is the first randomized controlled trial comparing endovascular therapy to open surgical bypass in patients with CLI to be carried out in North America. This landmark comparative effectiveness trial aims to provide Level I data to clarify the appropriate role for both treatment strategies and help define an evidence‐based standard of care for this challenging patient population. Clinical Trial Registration: URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 02060630.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.116.003219

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 232

Metadata

Authors
Menard, M. T., Farber, A., Assmann, S. F., Choudhry, N. K., Conte, M. S., Creager, M. A., Dake, M. D., Jaff, M. R., Kaufman, J. A., Powell, R. J., Reid, D. M., Siami, F. S., Sopko, G., White, C. J., & Rosenfield, K.
Venue
Journal of the American Heart Association
Published
2016-07-06
Volume
5
Issue
7
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2465379097
Cited by
232
References
8
FWCI
23.90
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST‐CLI) Trial. https://app.cochat.ai/papers/10.1161/jaha.116.003219
The paper
Menard, M. T., Farber, A., Assmann, S. F., Choudhry, N. K., Conte, M. S., Creager, M. A., Dake, M. D., Jaff, M. R., Kaufman, J. A., Powell, R. J., Reid, D. M., Siami, F. S., Sopko, G., White, C. J., & Rosenfield, K. (2016). Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST‐CLI) Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.116.003219

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.